Business Wire

Sandvine: Our Next Chapter as a Market Leader for Technology Solutions

Share

With new owners, a commitment to new leadership, and reoriented business model, today we announce the next chapter of Sandvine as a technology solution leader for democracies.

Our technology facilitates internet access for hundreds of millions of people around the globe. We work with the world’s largest internet service providers to classify network traffic, enhance network connectivity, and counter threats to network security. Our mission is to help people work, learn, entertain and communicate. In response to concerns regarding the misuse of our technology by foreign governments, we made a commitment to new ownership, leadership, and business strategy. In the last several months, we have committed to significant changes to our governance and business model in consultation with the U.S. Department of Commerce, the U.S. Department of State, and other key members of the U.S. government.

These transformative changes include:

  • Focusing Our Global Operations to Democracies in Support of Internet Freedom and Digital Rights. We believe that the best way to consistently and reliably prevent, detect, and deter misuse of our technology is to exit jurisdictions that lack a consistent, demonstrable commitment to internet freedom and strong rule of law protections. After conducting a full review of our business in jurisdictions that lack such commitments, we will no longer operate in non-democratic countries or countries where the threat to digital rights is too high.1 Accordingly, we have already exited 32 countries and are in the process of exiting an additional 24 countries, with an end-of-service date of March 31, 2025 (for Government of Egypt customers) and December 31, 2025 (for remaining Egyptian customers and all other identified countries).2 We are not just taking this new approach because it’s the right thing to do—we are implementing a viable business strategy that positions us to remain a technological leader and to provide indispensable service for our customers.
  • Dedicating 1% of All Profits to Protecting Digital Rights. We are committed to being a leader within our industry in the important fight to protect internet freedom and digital rights. In addition to our new democracy-only go-to-market plan, starting in 2025 we will donate 1% of future profits to organizations dedicated to protecting internet freedom and remediating instances of human rights and digital abuse. We should all do our part to ensure that all can enjoy an open and democratized internet, and hope our commitment inspires our peers to do the same.
  • Adding Digital Rights Expertise to Our Team. To guide our new mission and anticipate emerging human rights risks, we will retain and consult with outside advisors with deep expertise in understanding the global risks to digital rights. This initiative includes adding a senior advisor who will report directly to the Board of Directors to counsel on emerging risks and help prevent future product misuse, as well as help us better engage relevant non-governmental organizations and civil society to facilitate the protection of basic freedoms on the internet. This senior advisor will also report to the Board’s newly created Human Rights Subcommittee, which will exercise oversight over the company’s new governance and compliance controls, including a structure to prevent human rights and ensure export control compliance.
  • New Engagement with Civil Society. We are committed to having better relationships and consultations with civil society and affected stakeholders, both to understand how we can support digital rights and to understand the risks of future geopolitical and human rights risks. We will seek more engagement with human rights groups and other stakeholders, including those recommended by the U.S. Department of State, prior to expanding business operations to new jurisdictions.
  • Adopting New Controls for Ongoing Business Operations. For countries where we plan to remain, we will monitor for reports and signs of product misuse by customers through a new program that prioritizes human rights due diligence (“HRDD”).3 Relevant business decisions will undergo scrutiny through a Business Ethics Committee (“BEC”), which will seek input from outside policy advisors, as well as outside counsel who have significant prior government experience combatting human rights abuses. The BEC will identify and assess countries and territories with a history of blocking or censoring websites or social media platforms or using spyware, data analytics, and other forms of internet restrictions or surveillance to commit human rights abuses and infringe upon the rule of law.
  • New Owners and Leadership. This summer, a group of institutional investors committed to driving the evolution of our company forward replaced prior ownership. Our new owners have already appointed a new Board that, aided by a human rights advisor and other resources, can oversee the company’s new direction. Likewise, with this chapter successfully behind us, our current CEO has announced his intention to step down. The company has initiated a search and selection process for a new CEO with human-rights focused leadership who will continue the company’s progress toward our new democratically focused business model.
  • New Name. Starting in2025,we will operate under a new name that reflects our leadership in protecting digital rights. While we will not ignore what has happened in the past, we are eager for a new brand that customers and the public will come to know as a leader in the way companies can shape their business and governance to promote a free, reliable, and accessible internet.

The misuse of deep packet inspection technology is an international problem that threatens free and fair elections, basic human rights, and other digital freedoms we believe are inalienable. Over the last several years, there have been instances where we believe our products were misused by foreign governments in order to infringe on civil liberties and other rights. In the past, we responded through different legal and technological methods available to us. Unfortunately, we have concluded that such steps are not enough, and what is required is a more dramatic shift in the markets in which we operate and in the way that we do business. We recognize this decision may be disruptive, and we are committed to exiting markets in a way that maintains internet connectivity to the millions of subscribers our customers serve.

We acknowledge past misuse of Sandvine’s products, as well as the fact that the company’s response to past reports of misuse was insufficient. We also unequivocally condemn any misuse of our products to facilitate repression, limit freedom of expression, restrict freedom of association, monitor journalists and political dissidents, and disrupt democratic elections. In that vein, and with the changes outlined today, we are now well positioned to be an industry leader that forcefully pushes back on authoritarian governmental use of technology to undermine democratic norms and abuse basic human rights.

As we embark on this new chapter as a technology solution leader for democracies, we are especially thankful to our customers and business partners for their continued support and steadfast fidelity to our purpose. We are, and will remain, committed to improve because we believe access to digital communication and its benefits bolsters the values and interests of democracy.

____________________
1 This decision was based on a review of our operations using a variety of government and external references, including the U.S. Department of State Country Reports on Human Rights Practices, the Reporters Without Borders’ 2023 World Press Freedom Index, and Freedom House’s 2024 Internet Freedom Scores. We made the decision to exit all countries categorized as “non-democratic” in the Economist Intelligence Unit’s 2023 Democracy Index, which is available here.
2 In the interim period before exiting these jurisdictions, Sandvine will maintain contractual authority to act on violations of the end-user license agreement.
3 Our new HRDD program will look to implement enhanced measures and transparency in line with the U.S. State Department’s Guidance on Implementing the UN Guiding Principles for Transactions Linked to Foreign Government End-Users for Products or Services with Surveillance Capabilities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240919441171/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye